To combat the dreaded diseases in rice like bacterial blight and blast, host plant resistance has been advocated as a sustainable method. Through the present study, we have successfully incorporated three major bacterial blight (BB) resistance genes viz., Xa21, xa13 and xa5 into NLR3449, a high yielding, blast resistant, fine-grain type popular rice variety through marker-assisted backcross breeding. Foreground selection was carried out using PCR based, gene-specific markers viz., pTA248 (Xa21), xa13prom (xa13) and xa5FM (xa5) at each generation of backcrossing, while 127 polymorphic SSR markers spanning on 12 chromosomes were used for background selection and backcrossing was limited to two rounds. At BC2F1 generation, a single plant (NLR-87-10) with 89.9% recovery and possessing all the three bacterial blight resistance genes was forwarded to BC2F2 generation. A solitary BC2F2 plant viz., NLR-87-10-106 possessing all the three resistance genes and > 90% genome recovery was identified and advanced through selfing till BC2F4 generation by adopting pedigree method. Three best lines at BC2F4 lines, possessing high level of resistance against bacterial blight and blast and equivalent or superior to NLR 34449 in terms of yield, grain quality and agro-morphological traits have been identified and advanced for multi-location trials.
Introduction: Mucoceles are the most common benign lesions of the oral cavity developing as a result of retention or extravasation of mucus from the minor salivary glands. There are various treatment modalities which include excision, laser ablation, cryosurgery, sclerotherapy, micro marsupialization, and intra-lesional injection of sclerosing agent or corticosteroid. Although surgery is widely used, it has several disadvantages such as bleeding, lip disfigurement and damage to adjacent ducts with further development of satellite lesions. Kshara being an Anusastra possessing Chedana, Bhedana, Lekhana, Pachana, Vilayana, Shodhana, Ropana, Shoshana and Stambhana Karmas will address all the difficulties faced during conventional ways of treatments. The current study was undertaken to introduce, validate and standardise novel, minimally invasive, para surgical approach towards the treatment of oral mucocele. Methodology: Teekshna Pratisaraniya Apamarga Kshara was prepared. Clinical study was conducted on 30 subjects diagnosed with oral mucocele. Ksharakarma was done. For statistical analysis of parametric values, Repeated period ANOVA test within the group and for non-parametric values, Friedman’s Test within the group were used. Result: The comprehensive analysis of all the results reveals that, all the parameters showed significant change both statistically and clinically with no side effects or complication. Discussion: Ksharakarma on oral mucocele acts by tissue necrosis, gradual sloughing off followed by healing of remnant ulcer with epithelialisation, which was found to be an effective, minimally invasive, para surgical management of oral mucocele without any complications.
What started as a small cluster of viral pneumonia like cases in a province of China, in the early weeks of December, has blown out to be a full-fledged pandemic virtually affecting every continent. PubMed and Google search engines were used for literature search. The case fatality rate which is around 2.6% for corona virus disease (COVID-19) patient’s rise to nearly 10.6% in COVID-19 patients with prior cardio vascular disease. Common cardiac manifestations include heart failure and myocardial damage. Angiotensin converting enzyme (ACE2) plays an important part in the pathophysiology of heart function in hypertension and diabetes, two of the most common manifestations of heart failure and is the cellular entry point for the severe acute respiratory syndrome (SARS) virus. Patients with cardio vascular disease are believed to have increased secretion of ACE2 compared to healthy individuals and thus are at higher risk. Patients on medications with angiotensin converting enzyme inhibitor (ACEi) /angiotensin receptor blocker (ARB) have increased ACE2 levels and may be at an increased risk, however there is no statistically significant data to substantiate this claim.
Introduction: Fissure-in-ano is an ulcer in the longitudinal axis of lower anal canal. It is having prevalence of about 17.91%. By seeing the signs and symptoms we can consider it as one among the six varieties of Dushta Vrana i.e., Pittaja Dustavrana. Due to busy life schedules people don’t prefer hospitalization and other operative procedures. So, there is a need to find out a new and simpler medicament which enables easy and better storage, preservation and mode of application. Here an attempt was made to study the effect of Nirvapana Upakrama in the management of fissure in ano is taken. This Upakrama is used for the treatment of Vrana accompanied with Daha, Paka, Jwara and having Pitta Kopa and Raktena Abhibhuta. Since fissure is having the similar symptoms this treatment can be adopted for the management of the same. Methodology: A randomized controlled clinical study was conducted over 30 subjects in two groups. Fifteen subjects were advised to apply Diltiazem gel and 15 subjects were advised to apply Durva ointment twice daily for a period of 14 days. Results: Rapid reduction in pain, burning sensation and length of ulcer was observed in the subjects who were given Durva ointment. Discussion: Durva ointment having Madura Rasa, Snigdha Guna and Sheeta Virya does Vatapitta Shamana and pacifies vitiated Rakta. Kashaya rasa of Durva does Vrana Ropana and Rakta Sthambana which amplifies in ulcer healing and relaxation of the sphincter.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.